share_log

10-Q: Q1 2025 Earnings Report

SEC ·  Sep 13 04:14

Summary by Futu AI

Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share for the quarter ended July 31, 2024. However, the company has disclosed its stock-based compensation expenses, which decreased year-on-year from $124,646 in 2023 to $54,554 in 2024. The company also reported a cumulative net operating loss for federal income tax purposes of approximately $56 million as of July 31, 2024, an increase from $54 million at the end of the previous fiscal year. Heart Test Laboratories has a long-term operating lease for its facilities, with rent expense for the quarter amounting to approximately $37,000. In terms of business development, the company has entered into collaboration agreements with Rutgers and Mount Sinai...Show More
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share for the quarter ended July 31, 2024. However, the company has disclosed its stock-based compensation expenses, which decreased year-on-year from $124,646 in 2023 to $54,554 in 2024. The company also reported a cumulative net operating loss for federal income tax purposes of approximately $56 million as of July 31, 2024, an increase from $54 million at the end of the previous fiscal year. Heart Test Laboratories has a long-term operating lease for its facilities, with rent expense for the quarter amounting to approximately $37,000. In terms of business development, the company has entered into collaboration agreements with Rutgers and Mount Sinai to develop AI-ECG algorithms, which are expected to enhance product development and expand clinical value. The company's future plans include seeking FDA clearances for its AI-ECG solutions and MyoVista wavECG device, with a 510(k) FDA submission targeted for the first quarter of 2025. Additionally, the company aims to submit its MyoVista Insights Cloud Platform and low ejection fraction algorithm for FDA review in mid-2025.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.